Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 256

1.

The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.

Smith JW, Moreira J, Abood G, Aranha GV, Nagda S, Wagner RH, Shoup M.

Am J Surg. 2009 Mar;197(3):308-12. doi: 10.1016/j.amjsurg.2008.10.010.

PMID:
19245906
[PubMed - indexed for MEDLINE]
2.

2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.

Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Cancer. 2004 Oct 15;101(8):1776-85.

PMID:
15386332
[PubMed - indexed for MEDLINE]
Free Article
3.

[Fluorodeoxyglucose-positron emission tomography in carcinoma of the esophagogastric junction].

Wang T, Sun YE, Chu XY, Tian JH, Liu Y.

Zhonghua Wai Ke Za Zhi. 2004 Jun 7;42(11):651-3. Chinese.

PMID:
15329251
[PubMed - indexed for MEDLINE]
4.

Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone.

Shenfine J, Barbour AP, Wong D, Thomas J, Martin I, Gotley DC, Smithers BM.

Dis Esophagus. 2009;22(8):668-75. doi: 10.1111/j.1442-2050.2009.00941.x. Epub 2009 Feb 13.

PMID:
19222534
[PubMed - indexed for MEDLINE]
5.

Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.

Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA.

Cancer. 2005 Oct 15;104(8):1620-6.

PMID:
16118804
[PubMed - indexed for MEDLINE]
Free Article
6.

Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.

Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA.

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1925-32. Epub 2007 Aug 7.

PMID:
17680242
[PubMed - indexed for MEDLINE]
7.

The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.

Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, Ajani JA.

Cancer. 2009 Nov 15;115(22):5184-92. doi: 10.1002/cncr.24604.

PMID:
19685531
[PubMed - indexed for MEDLINE]
Free Article
8.

Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.

Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60. Review.

PMID:
15464463
[PubMed - indexed for MEDLINE]
9.

Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.

Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA.

Mol Imaging Biol. 2009 Jan-Feb;11(1):54-60. doi: 10.1007/s11307-008-0169-9. Epub 2008 Sep 4.

PMID:
18769974
[PubMed - indexed for MEDLINE]
10.

[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.

Vallböhmer D, Hölscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R, Mönig SP.

J Surg Oncol. 2010 Aug 1;102(2):135-40. doi: 10.1002/jso.21592.

PMID:
20648583
[PubMed - indexed for MEDLINE]
11.

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.

Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.

BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266.

PMID:
21702914
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.

Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.

J Gastrointest Cancer. 2012 Dec;43(4):612-8. doi: 10.1007/s12029-012-9412-3.

PMID:
22777832
[PubMed - indexed for MEDLINE]
13.

Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.

Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):358-63. Epub 2007 May 29.

PMID:
17532577
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer.

Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, Fukuchi M, Oriuchi N, Endo K, Kuwano H.

Cancer. 2009 Jul 15;115(14):3196-203. doi: 10.1002/cncr.24399.

PMID:
19472406
[PubMed - indexed for MEDLINE]
Free Article
15.

Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.

Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, Kimura H, Faried A, Saito K, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Nonaka T, Shioya M, Ishikawa H, Sakurai H, Nakano T, Kuwano H.

Anticancer Res. 2007 Jul-Aug;27(4C):2627-33.

PMID:
17695425
[PubMed - indexed for MEDLINE]
Free Article
16.

Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, Goodman K, Rusch VW.

J Thorac Oncol. 2009 Jul;4(7):875-9. doi: 10.1097/JTO.0b013e3181a8cebf.

PMID:
19487968
[PubMed - indexed for MEDLINE]
17.

Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.

Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW Jr, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):471-7. doi: 10.1016/j.ijrobp.2011.12.029. Epub 2012 Feb 28.

PMID:
22381904
[PubMed - indexed for MEDLINE]
18.

Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.

Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH.

Dis Esophagus. 2008;21(2):151-8. doi: 10.1111/j.1442-2050.2007.00732.x.

PMID:
18269651
[PubMed - indexed for MEDLINE]
19.

Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer.

Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K.

Am J Surg. 2002 Sep;184(3):279-83.

PMID:
12354600
[PubMed - indexed for MEDLINE]
20.

Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.

Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, Ajani JA.

Cancer. 2009 Feb 1;115(3):624-30. doi: 10.1002/cncr.24056.

PMID:
19130466
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk